Scientists identify a new Alzheimer's trigger and a drug candidate that blocks it

Alzheimer's treatment debate over the past decade has been dominated by therapies targeting the amyloid beta protein; antibodies such as lecanemab and donanemab were approved in the United States and Europe in 2024-25 with mixed-but-positive results. A new study described by Science Daily identifies an enzyme that acts earlier in the disease pathway and is targetable.

The research, published in Cell Reports, was led by teams at Stanford University School of Medicine and Lyon Medical University. The researchers showed that a kinase known as TBK1 is markedly activated in synaptic loss and microglial inflammation processes in mouse models. TBK1 had previously been under investigation in other neurodegenerative diseases.

The critical finding was that a preclinical selective small-molecule TBK1 inhibitor reversed synaptic loss by around 60 percent and produced significant differences from controls in memory tests. Lead author Dr Lily Wong said the observation that TBK1 functions independently of the amyloid pathway opens the door to combination therapy.

Dr Wong's team explained the effect as a rebalancing of abnormal synapse pruning by phagocytic microglia. Inhibiting TBK1 signals microglia to stop engulfing healthy synapses, a finding consistent with the neuroinflammation hypothesis of Alzheimer's. The study also reduced plaque burden in advanced mouse models.

Imperial College London neurologist Dr Anna Dickenson, commenting to Science Daily on the clinical translation, said that because TBK1 is a tightly regulated kinase, selectivity will be critical. She noted that if researchers can leave other necessary kinase functions for cellular communication intact, the path forward looks promising. Dickenson called for an accelerated phase 1 safety study.

When the clinical effect of current amyloid-targeted drugs is examined, treatment groups have shown a difference of about 0.45 points per year on scales scored out of 27 to 35. The clinical significance of that effect remains debated. The TBK1 approach offers the hope of opening a different mechanism with a potentially different effect size.

In terms of funding, the Alzheimer's Drug Discovery Foundation (ADDF) and Stanford University have accepted a core grant; preclinical work could reach an IND filing in early 2027. ADDF has aggressively expanded its support for multi-target strategies over the past three years.

The study also reports TBK1 hyperactivation in human post-mortem tissue samples. These samples were sourced from the Boston University Alzheimer Brain Bank and showed a correlation between cognitive decline and active TBK1 signalling.

On safety, the effect of sustained TBK1 pathway intervention on innate immunity will be a key area of scrutiny. The kinase also plays a role in the type 1 interferon response to viral infections. The team noted that a phase 1 protocol could include viral-infection monitoring arms.

In the broader picture, the TBK1 strategy is seen as part of a shift from a single-target drug approach to a multi-pathway and combination approach. The Science Daily report shows that doors beyond the amyloid gate in Alzheimer research are continuing to open; experts say it will take 18 to 24 months to see how the clinical translation plays out. This is not medical advice.